查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1584735

过敏疫苗市场：按过敏类型、疫苗类型、应用、最终用户分类 - 全球预测 2025-2030

Allergy Vaccine Market by Allergy Type, Vaccine Type, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年过敏疫苗市值为12.8亿美元，预计2024年将达14.3亿美元，复合年增长率为11.51%，到2030年将达27.5亿美元。

过敏疫苗市场包括透过使免疫系统对过敏原脱敏来治疗或预防过敏反应而开发的疫苗。该市场包括各种类型的疫苗，例如皮下免疫疗法（SCIT）和舌下免疫疗法（SLIT），主要针对花粉、尘螨和食物过敏原等过敏。过敏疫苗的需求源自于全世界过敏性疾病的日益流行，这些疾病影响数百万人，并对生活品质和医疗保健系统产生重大影响。这些疫苗的应用对于控制症状和降低严重过敏反应的风险至关重要，使其在临床环境和过敏患者的日常管理中都很有价值。最终用途范围包括医院、诊所和家庭的弹性治疗。推动成长的关键因素包括对过敏性疾病认识的提高、生物技术的进步以及政府支持免疫治疗研究的倡议。新的商机在于个人化疫苗，利用基因组学根据个人免疫特征客製化治疗方法。生物技术公司和医疗保健提供者之间的合作可以促进更快的创新和采用，并确保可及性和可负担性。然而，市场成长面临严格的监管途径、研发成本高以及新兴市场认知度和接受度低等限制。此外，副作用和长期疗效的问题可能会让一些患者望而却步。为了解决这些问题，需要加强并广泛接受有关利益和风险的教育宣传活动。研究和创新可以集中在增强疫苗输送方法，包括研究奈米颗粒技术以提高疗效和患者依从性。此外，解决鲜为人知的过敏类型，例如环境过敏原和化学过敏原，可能会扩大治疗范围。因此，这些领域的创新需要在技术力和策略市场教育之间取得平衡，以推动接受并克服挑战，以确保在全球过敏症患者数量不断增长的背景下取得稳步进展。

主要市场统计
基准年[2023] 12.8亿美元
预测年份 [2024] 14.3亿美元
预测年份 [2030] 27.5亿美元
复合年增长率（%） 11.51%

市场动态：揭示快速发展的过敏疫苗市场的关键市场洞察

供需的动态交互作用正在改变过敏疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球过敏流行率不断上升
    • 工业化导致空气污染加剧
    • 提高消费者对过敏的认知
  • 市场限制因素
    • 有限的过敏疫苗生产商
  • 市场机会
    • 特定过敏疫苗生产研发
    • 政府和私营部门在疫苗生产上的努力
  • 市场挑战
    • 过敏疫苗的生产是资本集中的

波特五力：驾驭过敏疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解过敏疫苗市场的外部影响

外部宏观环境因素对影响过敏疫苗市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解过敏疫苗市场的竞争状况

过敏疫苗市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵过敏疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估过敏疫苗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了过敏疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，过敏疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球过敏盛行率正在上升
      • 工业化导致空气污染加剧
      • 提高消费者对过敏的认知
    • 抑制因素
      • 有限过敏疫苗製造商
    • 机会
      • 特定过敏疫苗生产的研发
      • 政府和私营部门在疫苗生产上的努力
    • 任务
      • 过敏疫苗的生产是资本集中的
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章过敏疫苗市场：依过敏类型

  • 过敏性气喘
  • 猫皮屑过敏
  • 草花粉敏感度
  • 花生过敏
  • 季节性过敏性鼻炎
  • 树花粉过敏

第七章过敏疫苗市场：依疫苗类型

  • 猫过敏疫苗
  • 屋尘螨过敏疫苗
  • 注射型 MPL 过敏疫苗
  • 花生过敏疫苗
  • 豚草过敏免疫疗法疫苗

第八章过敏疫苗市场：依应用分类

  • HIV
  • 肿瘤学
  • 呼吸系统

第九章过敏疫苗市场：依最终用户分类

  • 居家护理
  • 医院
  • 专科诊所

第十章美洲过敏疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太过敏疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲过敏疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • ALK-Abello, Inc.
  • Allergy Therapeutics PLC
  • Angany Inc.
  • Astellas Pharma Inc.
  • Biomay AG
  • DBV Technologies SA
  • Enesi Pharma Limited
  • Immunomic Therapeutics, Inc.
  • Jubilant Pharma Limited
  • LETI Pharma, SLU
  • Merck & Co., Inc.
  • Novartis AG
  • Sementis Ltd.
  • Stallergenes Greer International AG
  • Sunstone by Anergis SA
  • Thermo Fisher Scientific Inc.
Product Code: MRR-436901065A74

The Allergy Vaccine Market was valued at USD 1.28 billion in 2023, expected to reach USD 1.43 billion in 2024, and is projected to grow at a CAGR of 11.51%, to USD 2.75 billion by 2030.

The allergy vaccine market involves vaccines developed to treat or prevent allergic reactions by desensitizing the immune system to allergens. This market encompasses various vaccine types, such as subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), primarily addressing allergies like pollen, dust mites, and food allergens. The necessity for allergy vaccines is driven by the increasing prevalence of allergic disorders globally, which affect millions and significantly impact the quality of life and healthcare systems. The application of these vaccines is crucial in managing symptoms and reducing the risk of severe allergic reactions, making them valuable in both clinical settings and everyday management for allergy sufferers. The end-use scope includes hospitals, clinics, and home settings for treatment flexibility. Key factors catalyzing growth include heightened awareness of allergic conditions, advances in biotechnology, and government initiatives supporting immunotherapy research. Emerging opportunities lie in personalized vaccines, leveraging genomics to tailor treatments to individual immune profiles. Collaborations between biotech firms and healthcare providers can facilitate faster innovation and adoption, ensuring accessibility and affordability. However, market growth faces limitations such as stringent regulatory pathways, high R&D costs, and limited awareness or acceptance in emerging markets. Additionally, side effects and long-term efficacy questions may deter some patients. Addressing these could involve increasing educational campaigns about allergy vaccine benefits and risks to broaden acceptance. Research and innovation could focus on enhancing vaccine delivery methods, such as exploring nanoparticle technologies for improved efficacy and patient compliance. There's also potential in addressing under-represented allergy types, like environmental and chemical allergens, expanding treatment horizons. Consequently, innovating in these areas will require a balance of technical prowess and strategic market education to drive acceptance and overcome challenges, ensuring steady market growth against the backdrop of increasing global allergic incidences.

KEY MARKET STATISTICS
Base Year [2023] USD 1.28 billion
Estimated Year [2024] USD 1.43 billion
Forecast Year [2030] USD 2.75 billion
CAGR (%) 11.51%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Allergy Vaccine Market

The Allergy Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of allergies globally
    • Increasing air pollution with industrialization
    • Rising awareness among consumers about the allergies
  • Market Restraints
    • Limited allergy vaccine manufacturers
  • Market Opportunities
    • Research and development for the production of specific allergy vaccine
    • Government and private sector initiatives in the production of vaccines
  • Market Challenges
    • Capital intensive in the production of allergy vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Allergy Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Allergy Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Allergy Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Allergy Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Allergy Vaccine Market

A detailed market share analysis in the Allergy Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Allergy Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Allergy Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Allergy Vaccine Market

A strategic analysis of the Allergy Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Allergy Vaccine Market, highlighting leading vendors and their innovative profiles. These include ALK-Abello, Inc., Allergy Therapeutics PLC, Angany Inc., Astellas Pharma Inc., Biomay AG, DBV Technologies SA, Enesi Pharma Limited, Immunomic Therapeutics, Inc., Jubilant Pharma Limited, LETI Pharma, S.L.U., Merck & Co., Inc., Novartis AG, Sementis Ltd., Stallergenes Greer International AG, Sunstone by Anergis SA, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Allergy Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Allergy Type, market is studied across Allergic Asthma, Cat Dander Allergy, Grass Pollen Hypersensitivity, Peanut Hypersensitivity, Seasonal Allergic Rhinitis, and Tree Pollen Hypersensitivity.
  • Based on Vaccine Type, market is studied across Cat Allergy Vaccine, House Dust Mite Allergy Vaccine, Injectable MPL Allergy Vaccine, Peanut Allergy Vaccine, and Ragweed Allergy Immunotherapy Vaccine.
  • Based on Application, market is studied across HIV, Oncology, and Respiratory.
  • Based on End User, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of allergies globally
      • 5.1.1.2. Increasing air pollution with industrialization
      • 5.1.1.3. Rising awareness among consumers about the allergies
    • 5.1.2. Restraints
      • 5.1.2.1. Limited allergy vaccine manufacturers
    • 5.1.3. Opportunities
      • 5.1.3.1. Research and development for the production of specific allergy vaccine
      • 5.1.3.2. Government and private sector initiatives in the production of vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Capital intensive in the production of allergy vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Allergy Vaccine Market, by Allergy Type

  • 6.1. Introduction
  • 6.2. Allergic Asthma
  • 6.3. Cat Dander Allergy
  • 6.4. Grass Pollen Hypersensitivity
  • 6.5. Peanut Hypersensitivity
  • 6.6. Seasonal Allergic Rhinitis
  • 6.7. Tree Pollen Hypersensitivity

7. Allergy Vaccine Market, by Vaccine Type

  • 7.1. Introduction
  • 7.2. Cat Allergy Vaccine
  • 7.3. House Dust Mite Allergy Vaccine
  • 7.4. Injectable MPL Allergy Vaccine
  • 7.5. Peanut Allergy Vaccine
  • 7.6. Ragweed Allergy Immunotherapy Vaccine

8. Allergy Vaccine Market, by Application

  • 8.1. Introduction
  • 8.2. HIV
  • 8.3. Oncology
  • 8.4. Respiratory

9. Allergy Vaccine Market, by End User

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Allergy Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Allergy Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Allergy Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ALK-Abello, Inc.
  • 2. Allergy Therapeutics PLC
  • 3. Angany Inc.
  • 4. Astellas Pharma Inc.
  • 5. Biomay AG
  • 6. DBV Technologies SA
  • 7. Enesi Pharma Limited
  • 8. Immunomic Therapeutics, Inc.
  • 9. Jubilant Pharma Limited
  • 10. LETI Pharma, S.L.U.
  • 11. Merck & Co., Inc.
  • 12. Novartis AG
  • 13. Sementis Ltd.
  • 14. Stallergenes Greer International AG
  • 15. Sunstone by Anergis SA
  • 16. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. ALLERGY VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. ALLERGY VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALLERGY VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALLERGY VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALLERGY VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALLERGY VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ALLERGIC ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CAT DANDER ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALLERGY VACCINE MARKET SIZE, BY GRASS POLLEN HYPERSENSITIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEANUT HYPERSENSITIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SEASONAL ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALLERGY VACCINE MARKET SIZE, BY TREE POLLEN HYPERSENSITIVITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALLERGY VACCINE MARKET SIZE, BY CAT ALLERGY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOUSE DUST MITE ALLERGY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALLERGY VACCINE MARKET SIZE, BY INJECTABLE MPL ALLERGY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALLERGY VACCINE MARKET SIZE, BY PEANUT ALLERGY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RAGWEED ALLERGY IMMUNOTHERAPY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALLERGY VACCINE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALLERGY VACCINE MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ALLERGY VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ALLERGY VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ALLERGY VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ALLERGY VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY ALLERGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ALLERGY VACCINE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 196. ALLERGY VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. ALLERGY VACCINE MARKET, FPNV POSITIONING MATRIX, 2023